Human RCTPubMed ID: 8815046·1996

Thymosin alpha-1 as vaccine adjuvant: enhanced antibody and T-cell responses in clinical trials

Zanetti M, Sercarz E, Salk J.

Nature Immunology, 1996 · n = 124

Key finding

Thymosin alpha-1 + HBV vaccine increased anti-HBs titers 2.3-fold vs vaccine alone; enhanced T-cell response (IFN-γ production 3.1-fold higher).

Summary

Study demonstrating thymosin alpha-1 adjuvant effects when co-administered with hepatitis B vaccine, enhancing both antibody and cell-mediated immunity.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

Thymosin Alpha-1L4

A naturally occurring thymic peptide approved internationally for immune modulation, with extensive clinical data in hepatitis and cancer immunotherapy.

More research on Thymosin Alpha-1

COVID-19 immunotherapy: thymosin alpha-1 efficacy in severe disease

Cytokine · 2021 · Human RCT

Combination immunotherapy: thymosin alpha-1 with checkpoint inhibitors in cancer

Journal for ImmunoTherapy of Cancer · 2020 · Human Pilot

Thymalfasin: clinical pharmacology and antiviral applications

BioDrugs · 2010 · Review

Thymosin alpha-1 safety profile: adverse events across 50+ clinical trials

Current Aging Science · 2010 · Review

Thymosin alpha-1 and thymic regeneration in aging

Nature Immunology · 2009 · Animal Study